Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 0 | 194 | 1 | 2 | 11 |
| TOTAL | $70 | $208 | $41 | $51 | $30 |
| Non-Current Assets | |||||
| Investments And Advances | 32,005 | 41,477 | 50,062 | 71,657 | 70,766 |
| TOTAL | $32,005 | $41,477 | $50,062 | $71,657 | $70,766 |
| Total Assets | $32,075 | $41,685 | $50,103 | $71,708 | $70,796 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 622 | 537 | 432 | 446 | 551 |
| TOTAL | $622 | $642 | $521 | $494 | $567 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,952 | 1,792 | 1,587 | 1,487 | 690 |
| Other Non-Current Liabilities | 24,501 | 34,251 | 42,995 | 64,727 | 64,539 |
| TOTAL | $26,452 | $36,043 | $44,582 | $66,213 | $65,229 |
| Total Liabilities | $27,075 | $36,685 | $45,103 | $66,708 | $65,796 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 272 | 607 | 692 | 904 | 904 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | 370 | 384 | 325 | 149 | -39 |
| TOTAL | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 |
| Total Liabilities And Equity | $32,075 | $41,685 | $50,103 | $71,708 | $70,796 |